Tag: US FDA

  • This is Why Moderna Could Run to $200, Near-Term

    This is Why Moderna Could Run to $200, Near-Term

    Vaccine news has created big opportunity. Look at BioNTech for example.  The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had a 95% effective rate with no safety concerns. “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,”Pfizer…

  • Moderna Inc. Could Have Vaccine by December 2020

    Moderna Inc. Could Have Vaccine by December 2020

    Keep an eye on Moderna Inc. (MRNA). The COVID-19 vaccine stock is regaining some lost ground.  All after CEO Stephane Bancel said the U.S. government could authorize emergency use of the company’s vaccine by December.  That is, if the company can produce positive interim results in November from its clinical trial. According to The Wall…